Investigating the Role of Y Chromosome Mutations in Autoimmune Diseases
Official title: Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases
Run by University of Bonn · NCT06696027 · Data updated 2026-11-12
This study is trying to see how changes in the Y chromosome might affect the immune system and contribute to autoimmune diseases like Giant Cell Arteritis and Polymyalgia Rheumatica.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years and up |
| Sex | Men only |
| Enrollment | 500 (estimated) |
| Sponsor | University of Bonn Academic / other |
| Locations | 1 site (Bonn, North Rhine-Westphalia) |
| Status | Recruiting |
| Started | November 15, 2024 |
| Main results expected | December 2025 |
| Study ends | July 2026 |
| Registry record updated | April 10, 2025 |
| Trial ID | NCT06696027 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are males over 50 years old diagnosed with specific autoimmune or rheumatologic conditions.
✕Probably not a fit
Patients who are female or under 50 years old will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The AYLo study focuses on understanding the impact of hematopoietic mutations, particularly the loss of the Y chromosome, on autoimmune rheumatologic diseases such as Giant Cell Arteritis and Polymyalgia Rheumatica. By employing advanced techniques like SNP arrays, mRNA sequencing, and flow cytometry, the study aims to uncover how these mutations affect immune function and disease progression. This observational research seeks to fill knowledge gaps regarding the mechanisms driving inflammation and susceptibility in these conditions.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of autoimmune diseases, potentially enhancing patient outcomes.
How similar studies have gone: While the specific focus on Y chromosome mutations in this context may be novel, similar studies exploring genetic factors in autoimmune diseases have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male * \> 50 years * Diagnosis of arthritis (RA, PsA), collagen diseases (SLE, systemic sclerosis, Sjögren's syndrome, mixed connective tissue diseases), vasculitis (eGPA, GPA, MPA, IgG4-related disease, GCA, PMR), sarcoidosis, COPD, ILD or asthma bronchiale confirmed by the treating physician. Exclusion Criteria: * Female * \< 50 years Inclusion Criteria (Healthy controls): * Male * \> 50 years Exclusion Criteria (Healthy controls): * Female * \< 50 years * autoimmune, rheumatological diease * pulmonary precondition
Where it's running
-
Department of Rheumatology
Bonn, North Rhine-Westphalia, Germany Recruiting
Study contacts
- Study coordinator: Simon Michael Petzinna, MD
- Email: Simon_Michael.Petzinna@ukbonn.de
- Phone: 0049 151 382 337 07
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized lab test to predict the best treatment for rheumatic diseases
This project tests a lab-based cell assay to see if it can predict which DMARD will work best for adults with autoimmune rheumatic diseases such as RA, PsA, axSpA, and GCA.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
Carotid ultrasound to guide prevention of heart disease in inflammatory rheumatic diseases
In people with inflammatory rheumatic diseases like RA, PsA, AxSpA, or SLE who are at modest cardiovascular risk, a carotid ultrasound test is used to see if they should start stronger lipid-lowering therapy to prevent heart problems.
-
Oxidative stress in autoimmune joint diseases
Researchers will see if oxidative stress and antioxidant markers differ in adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
-
MTS109 treatment for refractory autoimmune diseases
This trial tests whether MTS109 (an mRNA-LNP given by subcutaneous injection) is safe and tolerable in adults with moderate to severe autoimmune diseases that have not responded to standard treatments.
-
S-4321 in adults with autoimmune or immune-mediated diseases
This study tests S-4321 in adults with autoimmune conditions to see if it is safe and tolerable and to gather early data on how the drug behaves in the body and its initial effects on disease markers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.